You are here:

trametinib 0.5mg, 2mg film-coated tablets (Mekinist)

Advice

in the absence of a submission from the holder of the marketing authorisation:

trametinib (Mekinist®) is not recommended for use within NHS Scotland.

Indication under review: in combination with dabrafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: trametinib 0.5mg, 2mg film-coated tablets (Mekinist)
SMC Drug ID: 1264/17
Manufacturer: Novartis Pharmaceuticals UK Ltd
Indication: In combination with dabrafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 10 July 2017

Back